218 related articles for article (PubMed ID: 9521742)
1. Hydropathic analysis and mutagenesis of the catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5). cGMP versus cAMP substrate selectivity.
Turko IV; Francis SH; Corbin JD
Biochemistry; 1998 Mar; 37(12):4200-5. PubMed ID: 9521742
[TBL] [Abstract][Full Text] [Related]
2. A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.
Blount MA; Zoraghi R; Ke H; Bessay EP; Corbin JD; Francis SH
Mol Pharmacol; 2006 Nov; 70(5):1822-31. PubMed ID: 16926278
[TBL] [Abstract][Full Text] [Related]
3. Implications of PDE4 structure on inhibitor selectivity across PDE families.
Ke H
Int J Impot Res; 2004 Jun; 16 Suppl 1():S24-7. PubMed ID: 15224132
[TBL] [Abstract][Full Text] [Related]
4. Binding of cGMP to both allosteric sites of cGMP-binding cGMP-specific phosphodiesterase (PDE5) is required for its phosphorylation.
Turko IV; Francis SH; Corbin JD
Biochem J; 1998 Feb; 329 ( Pt 3)(Pt 3):505-10. PubMed ID: 9445376
[TBL] [Abstract][Full Text] [Related]
5. PDE5 is converted to an activated state upon cGMP binding to the GAF A domain.
Rybalkin SD; Rybalkina IG; Shimizu-Albergine M; Tang XB; Beavo JA
EMBO J; 2003 Feb; 22(3):469-78. PubMed ID: 12554648
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine-612 in PDE5 contributes to higher affinity for vardenafil over sildenafil.
Corbin J; Francis S; Zoraghi R
Int J Impot Res; 2006; 18(3):251-7. PubMed ID: 16281046
[TBL] [Abstract][Full Text] [Related]
7. Molecular cloning and expression of human cGMP-binding cGMP-specific phosphodiesterase (PDE5).
Stacey P; Rulten S; Dapling A; Phillips SC
Biochem Biophys Res Commun; 1998 Jun; 247(2):249-54. PubMed ID: 9642111
[TBL] [Abstract][Full Text] [Related]
8. A photoaffinity probe covalently modifies the catalytic site of the cGMP-binding cGMP-specific phosphodiesterase (PDE-5).
Corbin JD; Beasley A; Turko IV; Haik TL; Mangum KA; Wells JN; Francis SH; Sekhar KR
Cell Biochem Biophys; 1998; 29(1-2):145-57. PubMed ID: 9631243
[TBL] [Abstract][Full Text] [Related]
9. Probing domain functions of chimeric PDE6alpha'/PDE5 cGMP-phosphodiesterase.
Granovsky AE; Natochin M; McEntaffer RL; Haik TL; Francis SH; Corbin JD; Artemyev NO
J Biol Chem; 1998 Sep; 273(38):24485-90. PubMed ID: 9733741
[TBL] [Abstract][Full Text] [Related]
10. Molecular determinants of cGMP binding to chicken cone photoreceptor phosphodiesterase.
Huang D; Hinds TR; Martinez SE; Doneanu C; Beavo JA
J Biol Chem; 2004 Nov; 279(46):48143-51. PubMed ID: 15331594
[TBL] [Abstract][Full Text] [Related]
11. Studies of the molecular mechanism of discrimination between cGMP and cAMP in the allosteric sites of the cGMP-binding cGMP-specific phosphodiesterase (PDE5).
Turko IV; Francis SH; Corbin JD
J Biol Chem; 1999 Oct; 274(41):29038-41. PubMed ID: 10506154
[TBL] [Abstract][Full Text] [Related]
12. Potential roles of conserved amino acids in the catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase.
Turko IV; Francis SH; Corbin JD
J Biol Chem; 1998 Mar; 273(11):6460-6. PubMed ID: 9497379
[TBL] [Abstract][Full Text] [Related]
13. Specific cGMP binding by the cGMP binding domains of cGMP-binding cGMP specific phosphodiesterase.
Liu L; Underwood T; Li H; Pamukcu R; Thompson WJ
Cell Signal; 2002 Jan; 14(1):45-51. PubMed ID: 11747988
[TBL] [Abstract][Full Text] [Related]
14. Structural determinants of the PDE6 GAF A domain for binding the inhibitory gamma-subunit and noncatalytic cGMP.
Muradov H; Boyd KK; Artemyev NO
Vision Res; 2004; 44(21):2437-44. PubMed ID: 15358079
[TBL] [Abstract][Full Text] [Related]
15. Conformational conversion of PDE5 by incubation with sildenafil or metal ion is accompanied by stimulation of allosteric cGMP binding.
Corbin JD; Francis SH
Cell Signal; 2011 Oct; 23(10):1578-83. PubMed ID: 21620965
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds.
Turko IV; Ballard SA; Francis SH; Corbin JD
Mol Pharmacol; 1999 Jul; 56(1):124-30. PubMed ID: 10385692
[TBL] [Abstract][Full Text] [Related]
17. [3H]sildenafil binding to phosphodiesterase-5 is specific, kinetically heterogeneous, and stimulated by cGMP.
Corbin JD; Blount MA; Weeks JL; Beasley A; Kuhn KP; Ho YS; Saidi LF; Hurley JH; Kotera J; Francis SH
Mol Pharmacol; 2003 Jun; 63(6):1364-72. PubMed ID: 12761347
[TBL] [Abstract][Full Text] [Related]
18. Partial reconstitution of photoreceptor cGMP phosphodiesterase characteristics in cGMP phosphodiesterase-5.
Granovsky AE; Artemyev NO
J Biol Chem; 2001 Jun; 276(24):21698-703. PubMed ID: 11285263
[TBL] [Abstract][Full Text] [Related]
19. Conversion of phosphodiesterase-5 (PDE5) catalytic site to higher affinity by PDE5 inhibitors.
Blount MA; Zoraghi R; Bessay EP; Beasley A; Francis SH; Corbin JD
J Pharmacol Exp Ther; 2007 Nov; 323(2):730-7. PubMed ID: 17690252
[TBL] [Abstract][Full Text] [Related]
20. Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors.
Zoraghi R; Francis SH; Corbin JD
Biochemistry; 2007 Nov; 46(47):13554-63. PubMed ID: 17979301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]